超声内镜引导下胆囊引流与经皮胆囊造瘘术在极高危急性胆囊炎患者中的随机对照研究
这项国际多中心随机对照优效性试验纳入80例不适合胆囊切除术的急性结石性胆囊炎极高危患者,比较EUS-GBD与PT-GBD作为 definitive 治疗的效果。结果显示EUS-GBD显著降低1年不良事件率、30天不良事件率、30天后再次干预、非计划再入院及复发性胆囊炎,技术成功率、临床成功率和30天死亡率两组相似。EUS-GBD应作为首选,但需具备专业技术。
要点
- EUS-GBD较PT-GBD显著降低1年不良事件率(25.6% vs 77.5%)
- EUS-GBD组30天不良事件、再干预、再入院及复发胆囊炎均更少
- 两组技术成功率、临床成功率及30天死亡率无显著差异
核心结论
- 对于不适合胆囊切除术的急性胆囊炎极高危患者,EUS-GBD较PT-GBD改善结局。
- 在具备专业技术且经多学科讨论后,EUS-GBD应作为首选术式。
- 需进一步研究确定长期疗效。
研究设计与样本
- 国际随机多中心对照优效性试验(DRAC 1),纳入连续急性结石性胆囊炎且胆囊切除术极高危患者。
- 2014年8月至2018年2月共招募80例患者。
- 主要结局为1年不良事件率;次要结局包括技术和临床成功、30天不良事件、疼痛评分、非计划再入院、再干预和死亡率。
主要发现
- EUS-GBD组1年不良事件10例(25.6%),PT-GBD组31例(77.5%),p<0.001。
- EUS-GBD组30天不良事件5例(12.8%),PT-GBD组19例(47.5%),p=0.010。
- 30天后再次干预:EUS-GBD组1/39(2.6%),PT-GBD组12/40(30%),p=0.001。
- 非计划再入院:EUS-GBD组6/39(15.4%),PT-GBD组20/40(50%),p=0.002。
- 复发性胆囊炎:EUS-GBD组1/39(2.6%),PT-GBD组8/40(20%),p=0.029;PT-GBD是复发急性胆囊炎的预测因素(OR 5.63,95%CI 1.20-53.90,p=0.027)。
关键数值与推荐
- 技术成功率EUS-GBD 97.4% vs PT-GBD 100%,p=0.494。
- 临床成功率EUS-GBD 92.3% vs PT-GBD 92.5%,p=1。
- 30天死亡率EUS-GBD 7.7% vs PT-GBD 10%,p=1。
- 术后疼痛评分和镇痛需求EUS-GBD更少(p=0.034)。
临床怎么用
- 对于不适合胆囊切除术的极高危急性胆囊炎患者,EUS-GBD可替代PT-GBD作为 definitive 治疗。
- 实施EUS-GBD需具备相应专业技术,并建议经多学科讨论后决定。
局限性
- 样本量80例,可能影响部分次要结局的统计效能。
- 随访1年,长期疗效尚需进一步研究。
- 未报告设盲情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal management of acute cholecystitis in patients at very high risk for cholecystectomy is uncertain. The aim of the current study was to compare endoscopic ultrasound (EUS)-guided gallbladder drainage (EUS-GBD) to percutaneous cholecystostomy (PT-GBD) as a definitive treatment in these patients under a randomised controlled trial. DESIGN: Consecutive patients suffering from acute calculous cholecystitis but were at very high-risk for cholecystectomy were recruited. The primary outcome was the 1-year adverse events rate. Secondary outcomes include technical and clinical success, 30-day adverse events, pain scores, unplanned readmissions, re-interventions and mortalities. RESULTS: Between August 2014 to February 2018, 80 patients were recruited. EUS-GBD significantly reduced 1 year adverse events (10 (25.6%) vs 31 (77.5%), p<0.001), 30-day adverse events (5 (12.8%) vs 19 (47.5%), p=0.010), re-interventions after 30 days (1/39 (2.6%) vs 12/40 (30%), p=0.001), number of unplanned readmissions (6/39 (15.4%) vs 20/40 (50%), p=0.002) and recurrent cholecystitis (1/39 (2.6%) vs 8/40 (20%), p=0.029). Postprocedural pain scores and analgesic requirements were also less (p=0.034). The technical success (97.4% vs 100%, p=0.494), clinical success (92.3% vs 92.5%, p=1) and 30-day mortality (7.7% vs 10%, p=1) were statistically similar. The predictor to recurrent acute cholecystitis was the performance of PT-GBD (OR (95% CI)=5.63 (1.20-53.90), p=0.027). CONCLUSION: EUS-GBD improved outcomes as compared to PT-GBD in those patients that not candidates for cholecystectomy. EUS-GBD should be the procedure of choice provided that the expertise is available after a multi-disciplinary meeting. Further studies are required to determine the long-term efficacy. TRIAL REGISTRATION NUMBER: NCT02212717.
引用
- Teoh AYB, Kitano M, Itoi T, et al. Endosonography-guided gallbladder drainage versus percutaneous cholecystostomy in very high-risk surgical patients with acute cholecystitis: an international randomised multicentre controlled superiority trial (DRAC 1). Gut. 2020. PMID: 32165407. doi:10.1136/gutjnl-2019-319996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。